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Fungal atopy in adult cystic fibrosis
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This study set out to estimate the prevalence of atopy to a variety of common ubiquitous fungi, including
A. fumigatus, in cystic fibrosis (CF), and to evaluate the investigations by which the diagnosis was made. Particular
attention was paid to the usefulness of skin testing and immunoassays in detecting which patients had simple fungal
atopy, and which patients were at high risk of developing allergic bronchopulmonary mycoses.
This cross-sectional study included 21 adult CF patients and 20 matched controls. Serum samples were taken for
the measurement of total serum IgE and specific serum IgE to nine common fungi. Immediate hypersensitivity skin
prick testing to each of the fungi was also performed. Simple fungal atopy was described in subjects fulfilling the
following criteria: total serum IgE4100KU l71 with specific radioimmunoassay  grade 1 to at least one fungus
and a positive skin prick test (SPT)  3mm to the same fungus. ‘High risk’ for developing allergic
bronchopulmonary mycosis (ABPM) was described in subjects fulfilling the following criteria: total serum
IgE4200KU l71 with specific radioimmunoassay  grade 2 to at least one fungus and a positive skin prick test
(SPT)  6mm to the same fungus.
The adult CF group had a significantly higher total SPT score (P¼0?005) and mean total serum IgE (P5 0?05)
than controls. Forty-three percent of CF patients fulfilled the criteria for fungal atopy to at least a single fungus.
Over half this group had an atopic tendency to more than one fungus. Nineteen percent of the CF group were at
least ‘high risk’ of developing ABPM. Skin prick testing is a better marker of fungal atopy and a better predictor of
those adult CF patients at higher risk of developing ABPM than specific radioimmunoassay serum testing.
There is a high prevalence of fungal atopy in the adult CF population. Total serum IgE and skin prick testing are
good predictors of fungal atopy and help predict those at risk of developing ABPM in CF.
Key words: cystic fibrosis; fungal atopy; allergic bronchopulmonary mycosis (ABPM); skin prick test (SPT); specific
serum IgE (RAST).
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The incidence of Aspergillus fumigatus in the airways of
cystic fibrosis (CF) patients has been reported to be as high
as 57% (1). A minority (5–11%) (1–3) of these patients
develop allergic bronchopulmonary aspergillosis (ABPA).
To prevent lung damage, early and aggressive treatment
with high dose corticosteroids may be important (4). The
diagnosis of ABPA (bronchial obstruction, blood eosino-
philia, immediate skin reactivity to A. fumigatus, precipitat-
ing antibodies against A. fumigatus, elevated serum IgE
level, pulmonary infiltrates, central bronchiectasis, and
elevated A. fumigatus-specific IgE or IgG serum antibodies)
in CF patients may be more dicult to make than in non-
CF patients because of the overlap between the cardinal
clinical and paraclinical findings of ABPA (5,6) and those
of CF, including pulmonary infiltrates, intermittent wheez-Received 30 March 2000 and accepted in revised form 19 June
2000. Published online 26 September 2000.
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0954-6111/00/111092+05 $35?00/0ing and frequent colonization with A. fumigatus that leads
to humoral immunity.
Because of the frequent colonization with A. fumigatus in
CF, antibody reactivity to A. fumigatus proteins is
frequently observed. Likewise, the presence of positive skin
test to responses to A. fumigatus is common in CF patients.
It is not clear however, to what degree this atopic tendency
to A. fumigatus is a prognostic indicator of lung function
decline or morbidity in CF. Neither is it clear when fungal
atopy in CF merges into the clinical spectrum of full blown
ABPA. It has been suggested that sensitization to A.
fumigatus in patients with cystic fibrosis is, in itself,
associated with decreased lung function and poorer clinical
outcome (7,8). Both fungal atopy and ABPA are pre-
dominantly conditions affecting adult CF patients who tend
to have more severe pulmonary disease (9). It has been
suggested that while the incidence of ABPA is higher in
older CF patients, this cohort of patients do not have
significantly worse pulmonary disease than their counter-
parts who are colonized with A. fumigatus, without
fulfilling the diagnostic criteria for ABPA (10). Both of
these groups of patients had lower chest radiograph scores
than CF patients not colonized with A. fumigatus and both# 2000 HARCOURT PUBLISHERS LTD
TABLE 1. Comparison between adult CF patients and age
and sex matched controls, outlining differences between
group mean (SEM) total skin prick testing score (mm) and






Age (years) 22?1 (0?9) 24?2 (0?4)
Range 18–35 21–27
M:F 11:10 8:12
Skin prick test 6?76 0?7 *P¼0?005
Induration (mm) (2?0) (0?4)
Serum IgE 439?0 88?7 P¼0?05
(KU l71) (166?0) (26?1)
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oids.
Diagnostic cut-off levels along with positive and negative
predictive values of the various commonly used paraclinical
markers of ABPA in CF have remained speculative.
Specific IgE/IgG A. fumigatus antibodies detected by
ELISA have been proposed as having the power to
discriminate between patients with CF and ABPA and
those CF patients colonized with A. fumigatus, having
positive precipitins, but lacking the clinical and radio-
graphic evidence of ABPA (11,12). More recently Skov et
al. have described specific IgE antibodies, total serum IgE
and specific A. fumigatus immediate hypersensitivity skin
prick testing (SPT) along with A. fumigatus precipitins as
the most valid predictors of ABPA in CF (13). These
investigations tend to be more universally available in CF
units.
The incidence of allergic bronchopulmonary mycosis
(ABPM) and fungal atopy in CF involving common fungi
other than the Aspergillus species is unknown. Other fungi,
most commonly Candida albicans, have been reported to
cause this syndrome in chronic asthmatics (14,15). In India,
over 8% of patients with chronic respiratory disease have
been found to suffer from ABPM (16). In light of these
findings, we carried out a case-control study to determine
the levels of fungal atopy in an adult CF cohort as
determined by total serum IgE levels, specific IgE to
common fungi and specific skin prick testing to the same
fungi.
Patients and methods
We reviewed 21 adult CF patients (22?1+0?9, 18–35 years,
11 males) and 20 age and sex matched controls (24?2+0?4,
21–27 years, eight males). The CF patients attended the
adult CF outpatient clinic at the regional adult CF unit
(n¼40 adult CF patients) at Cork University Hospital,
Ireland. Patients had no evidence of a recent acute
exacerbation of respiratory disease requiring supplemen-
tary antibiotics or corticosteroids. Only one patient from
this group had suffered from proven ABPA using standard
criteria (6). The control population who were healthy
volunteers, had no history of atopic disease, including
asthma, allergic rhinnitis or eczema. The study was
approved by the local clinical research ethics committee.
Further investigations carried out included the following:
(a) serum samples were analysed for total IgE, using the
UniCAP automated immunoassay system 16 (Pharmacia,
Dublin, Ireland) according to the method of Paganelli et al.,
(17). Diagnostic levels consistent with fungal atopy were set
at  100KU l71. Diagnostic levels consistent ABPA or
ABPM or with high risk of developing either, were set at
 200 KU l71. (b) Specific serum IgE measurements, using
solid phase radioimmunoassay, to nine common fungi were
measured only if total serum IgE was4100KU l71. Serum
specific antibody measurements were carried out using the
UniCAP system described (17). The specific IgE antibodies
were assigned to (i) Aspergillus fumigatus, (ii) Candida
albicans, (iii) Cladosporidium herbarum, (iv) Penicilliumnotatum, (v) Helminthosporium halodes, (vi) Curvularia
lunata, (vii) Rhizopus nigricans, (viii) Alternaria alternata
and (ix) Mucor mucado. Responses were graded 0–4 as
described by the manufacturer as follows: immunoassay
class 0,  0?34 IUml71, class 1, 0?35–0?69 IUml71, class 2,
0?7–3?49 IUml71, class 3, 3?5–17?49 IUml71, class 4,
 17?5 IUml71. Diagnostic levels consistent with fungal
atopy were set at specific IgE  class 1. Diagnostic levels
consistent with ABPA or ABPM or with high risk of
developing either, were set at specific IgE class 2. (c) Type
I immediate hypersensitivity skin prick testing (SPT) to the
fungi outlined above was carried out using Allergo-Pharma
antigens (Allergo-Pharma Biodiagnostics, Worcestershire,
U.K.) with positive histamine and negative saline controls
measured on the opposite arm. Reactions were measured
after 15min. Wheals measuring  3mm in diameter after
15min were considered to be consistent with a diagnosis of
fungal atopy and wheals measuring  6mm in diameter
after15min were considered to be consistent with a
diagnosis of ABPA or ABPM or with high risk of
developing either. We adapted the anergy band Multitest
skin test method of measuring total skin induration induced
by all the fungi to give a total skin test score in mm for each
subject and control (18).
STATISTICS
Results are expressed as mean values +SEM and ranges
where appropriate. Statistical analysis was performed using
the Mann–Whitney U non-parametric analysis to compare
variables between groups. A w2-squared test was used to
determine independence. Sensitivity and specificity values
were determined in accordance with previously published
guidelines (23). The Instat II softwear package, (San Diego,
CA, U.S.A.) was used for statistical calculation. A two-
tailed P-value 50?05 was considered significant.
Results
Twenty-one CF patients, mean age 22?1+0?9 years took
part in this study. Results were compared to those of 20
1094 M. HENRY ET AL.matched control subjects, mean age 24?2+0?4 years. The
CF group had a significant higher mean total skin prick test
(SPT) score (CF: 6?76+2?0mm; control: 0?7+0?4mm;
P¼0?005) (Table 1). Likewise, the CF group had a
significantly higher mean serum IgE than the control group
(CF: 439?0+166?0KU l71; control: 88?7+26?1;P50?05).
These results demonstrate a substantial overall atopic
tendency to fungi in the CF group. The mean IgE and
SPT scores for the CF group are in the range described for
ABPM as outlined above (13). We quantified fungal atopy
and ‘high risk’ for ABPM in both the CF and control
population. The diagnoses were made on the basis of the
criteria outlined in Table 2, i.e. subjects with fungal atopy
satisfy all three criteria as follows: total IgE4100KU l71 at
least one specific IgE measurement 4class 1 and SPTTABLE 2. Outlines differences within the adult CF group, betw













‘A. fumigatus only’ group (n¼4)
Serum IgE ‘Overlap atopy’ group (n¼5) (KU l71)
Skin prick test
‘A. fumigatus only’ group (n¼4)
Skin prick test ‘Overlap atopy’ group (n¼5) (Induration mm)
ABPM ‘high risk’
Skin prick test ‘Overlap’ group (n¼0) (Induration mm)
IgE4200 (KU l71)





Serum IgE ‘A. fumigatus only’ group (n¼3)
Serum IgE ‘Overlap’ group (n¼0) (KU l71)
Skin prick test
‘A. fumigatus only’ group (n¼3)
Skin prick test ‘Overlap’ (n¼0)
(Induration mm)
Diagnostic criteria for fungal atopy include all of the following: (
prick test (SPT)53mm for the same fungus. Diagnostic cr
IgE4200KU l71, (2) RAST4class 2, (3) SPT56mm for the sam
groups fulfilling the criteria for fungal atopy and ABPM ‘high r
than a single fungus are included. 3mm to the same fungus. ABPM ‘high risk’ subjects
satisfy all three criteria as follows: total IgE4200KU l71,
at least one specific IgE measurement 4class 2 and
SPT  6mm to the same fungus. Nine out of 21 (43%)
adult CF patients fulfilled the criteria for fungal atopy to at
least one fungus on the basis of these three criteria
previously shown to have the strongest predictive value
(11) (Table 2). Our figures are higher than those previously
quoted for fungal atopy in CF populations (1) and may
reflect the effect of age in the adult only population studied,
the evaluation of atopy to fungi other than. A. fumigatus
and the increasing prevalence of aspergillus colonization in
the lower respiratory tracts of CF patients (11). In the
presence of a total IgE4100KU l71, we have demonstrated
that a SPT  3mm has a specificity for fungal atopy ofeen fungal atopy and allergic bronchopulmonary mycosis


























1) Total serum IgE4100KU l71, (2) RAST4class 1, 3. Skin
iteria for ABPM include all of the following: (1) Serum
e fungus. Mean (SEM) serum IgE and SPT values in the sub-
isk’ to A. fumigatus only and to an ‘overlap’ group to more
TABLE 3. Outlines the presence of fungal atopy or ABPM ‘high risk’ within the case and control populations. The individual
fungi studied are shown in italics. Similar diagnostic criteria for fungal atopy and ABPM are used as in Table 2
Fungal atopy
IgE 100KU l71




Specific IgE class 2
SPT 6mm
Case (n¼9) Control (n¼0) Case (n¼4) Control (n¼0)
A. fumigatus 9 0 3 0
P. notatum 4 0 0 0
C. herbarum 3 0 0 0
C. albicans 2 0 0 0
A. alternaria 2 0 1 0
M. mucado 0 0 0 0
R. nigricans 0 0 0 0
H. halodes 0 0 0 0
C. lunata 0 0 0 0
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80%. It is worth noting that none of the control subjects
fulfilled the diagnostic criteria for fungal atopy on the basis
of these three diagnostic criteria alone.
Four CF patients (19%) had all three diagnostic criteria
for ABPM ‘high risk’. Three of these patients fulfilled our
criteria for allergic bronchopulmonary aspergillosis
(ABPA) and the fourth fulfilled the criteria for allergic
bronchopulmonary alternariosis. SPT 6mm for an indi-
vidual fungus was 100% specific in this group, however
specific IgE4class 2 was only 66% specific for the diagnosis
of ABPM in this small group of CF patients. Once again
none of the control group fulfilled the ABPM criteria.
As previously outlined, fungal atopy itself can be a
predictor of poor respiratory function in CF. It is
important to highlight that of the nine fungi tested, the
CF group demonstrated atopy to five fungi: in order of
frequency these included A. fumigatus (n¼9), P. notatum
(n¼4), C. herbarum (n¼3), C. albicans (n¼2) and A.
alternata (n¼2) (Table 3). There are overlap of fungal
atopy to more that one fungus in five (55%) adult CF
patients. These ‘overlap atopy’ syndromes occurred to the
following combination of fungi: patient 3, A. fumigatus þ
P. notatum þ A. alternata; patient 4, A. fumigatus þ P.
notatum þ A. alternata þ C. herbarum þC. albicans; patient
6, A. fumigatus þ P. notatum þ C. herbarum; patient 7, A.
fumigatus þ C. albicans; patient 9, A. fumigatus þ P.
notatum þ C. herbarum. All four CF patients with ABPM
‘increased risk’ were allergic to a single fungus only.
Discussion
The experience of allergic bronchopulmonary aspergillosis
in patients with CF suggests that there should be an
increased awareness of the condition and its capacity tocause significant pulmonary morbidity. The concomitant
physical and radiological signs of ABPA and CF have led
to confusion and delay in making this very important
diagnosis in CF. Greenberger has defined separate isotypes
of ABPA with and without central bronchiectasis in
asthmatics (6). The importance of concentrating on
serological and immediate hypersensitivity skin testing in
order to make the diagnosis of ABPA and indeed, ABPM
in cystic fibrosis, has been highlighted in several recent
papers (11,19–21). This study confirms the high prevalence
of fungal atopy in CF. We have not attempted to relate
these findings to pulmonary function. Previous studies
which have attempted to do this have shown conflicting
results (3,7,8), however none of these studies have tried to
correlate a fall in pulmonary function over time with the
presence or absence of the paraclinical findings outlined in
this paper. This study uses recently suggested diagnostic
criteria (13,19,20) for ABPA and fungal atopy to A.
fumigatus in CF and extends the criteria to include other
common fungi, which may cause fungal atopy and ABPM
in CF.
While others have highlighted the importance of a rise in
total serum IgE (13), specific IgG subclasses (21), A.
fumigatus precipitins (11,13,19,20) and SPT-A. fumigatus
(11,13,19) as serological predictors of ABPA in CF, this
study suggests that in the presence of a serum IgE4100
KU l71, a SPT result  3mm for a specific fungus is
sucient to make the diagnosis of fungal atopy. Using the
paraclinical parameters of a serum IgE4200 KU l71 and a
SPT result 6mm for an individual fungus we identified a
group of CF patients who are at least at ‘high risk’ of
developing ABPA and ABPM. The addition of specific
serum IgE measurement adds little to the diagnostic panel,
however in the absence of skin testing facilities, specific
IgE class 1 for fungal atopy or  class 2 for ABPM are
also suggestive markers.
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variety of common fungi in our adult CF patients. We also
suggest that on the basis of the criteria used that four out of
twenty-one (21%) CF patients suffered from ABPM or were
at high risk of developing ABPM with A. fumigatus being
the offending fungus in most but not all cases. While it is
suggested that prednisolone and itraconazole have a definite
role to play in the treatment of ABPA in asthma (4,22), it is
not clear whether treating these CF patients with fungal
atopy or ABPM would alter their disease status.
Our results demonstrate that greater awareness needs to
be shown, amongst clinicans treating CF patients, of the
possibility of either fungal atopy or ABPM within
the CF population. A narrower focus of diagnostic tests
concentrating on serum IgE, SPT and, to a lesser extent,
specific IgE immunoassay testing, is recommended to
diagnose fungal atopy and to highlight those who in the
correct clinical context should be considered for treat-
ment for ABPM. On the other hand a wider range of
fungi other than A. fumigatus need to be considered as
potential pathogens within an adult CF population. Our
results would suggest that it may be worthwhile concentrat-
ing on a panel of common fungi including A. fumigatus, P.
notatum, C. albicans, A. alternata and C. herbarum. Further
studies examining the effect of fungal atopy and ABPM on
pulmonary phenotype over time in CF are recommended.
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